Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Alzheimer's Disease Dementia
NCT07284472
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease dementia.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Agitation Associated With Alzheimer's Disease Dementia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2/3
- Ages
- 55 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Exciva GmbH
- Last updated on ClinicalTrials.gov
- August 14, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Esperanza Clinical · Murrieta, CA
Indiana · 1
- Josephson Wallack Munshower Neurology PC · Indianapolis, IN
Mississippi · 1
- Precise Research Centers · Flowood, MS
New York · 2
- Integrative Clinical Trials · Brooklyn, NY
- Manhattan Behavioral Medicine · New York, NY
Ohio · 1
- Insight Clinical Trials · Independence, OH
Vermont · 1
- The Memory Clinic · Bennington, VT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.